ClinicalTrials.gg
CompletedNCT01301729Updated Dec 29, 2016Results posted

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

A Phase 4 interventional study of Docetaxel and Paclitaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 17 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-29.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
266th of 366
32 · median 61
Started
2011
with 18 others
Phase 4
7 of 374
1 open now
Registered
164th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 266th largest by enrollment of the 366 interventional ones that give a count, is one of 19 that started in 2011, is one of 7 in phase 4, and was the 164th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with a taxane as first line therapy in participants with HER2-positive breast cancer who relapsed after neoadjuvant or adjuvant Herceptin treatment. Participants will receive Herceptin (loading dose of 4 mg/kg intravenously [iv], 2 mg/kg iv weekly thereafter) with 6 3-week cycles of either docetaxel (100 mg/m2 iv every 3 weeks) or paclitaxel (90 mg/m2 every week). Herceptin treatment will be continued until disease progression or unacceptable toxicity occurs.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants , >/= 18 years of age
  • Locally recurrent/ breast cancer (relapse in supra- or infraclavicular lymph nodes is regarded as metastatic disease)
  • -positive primary disease
  • Participants must have received Herceptin in the and/or neoadjuvant setting
  • breast cancer >/= 6 months after discontinuing last drugs of Herceptin and/or chemotherapy in the adjuvant and/or neoadjuvant setting for HER2-positive breast cancer
  • according to 1.0
  • (ECOG) performance status 0-2
  • Maximum cumulative dose of doxorubicin \</= 360 mg/m2 or of epirubicin \</= 720 mg/m2 or no prior anthracyclines
  • At least 3 weeks after prior surgery or radiotherapy

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Previous chemotherapy for breast cancer (prior endocrine therapy till progressive disease is allowed)
  • Pleural effusions, ascites or bone lesions as only manifestation of disease
  • Invasive other than metastatic breast cancer
  • Inadequate bone marrow, hepatic or renal function
  • Prior treatment with anti-HER therapies other than (neo)adjuvant Herceptin
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Trastuzumab

    Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m\^2), every 3 weeks or paclitaxel 90 mg/m\^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies.

    Drug: Docetaxel · Drug: Paclitaxel · Drug: Trastuzumab

Interventions

  • 100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)

  • 90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)

  • 4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 and was defined as the time from the date when the participant signed the informed consent form (ICF) until death or progressive disease (PD). PD was defined as 20% increase in the sum of the longest diameter of target lesions. PFS and associated confidence intervals were calculated using the Kaplan-Meier method.

    Time frame: From the date of informed consent to the date of death or progressive disease (up to 28 months)

Secondary outcomes

  1. Overall Response Rate

    Overall response rate was assessed using RECIST 1.0 and defined as the percentage of participants that achieved a complete response (CR) or a partial response (PR). CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions.

    Time frame: up to 28 months

  2. Duration of Response

    Duration of response was defined as the time from when a PR or CR was first documented until the date of documented PD or death. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. PD was defined as 20% increase in the sum of the longest diameter of target lesions.

    Time frame: From the time of PR or CR until the date of PD or death (up to 28 months)

  3. Overall Survival

    Overall survival was defined as the time from the date of enrollment to the date of death due to any cause.

    Time frame: Time from enrollment to the date of death (up to 28 months)

  4. Percentage of Participants With an Adverse Event (AE)

    An AE was defined as any adverse medical event that occurred after the participant used the investigational medicinal product (IMP) or other intervention behaviors specified by the protocol in the clinical trial regardless of relationship to the study treatment.

    Time frame: Up to 28 days after last infusion of the study drug (28 months)

  5. Determination of Biomarkers Indicative for Response (Serum and Tumour Tissue Analyses)

    Time frame: up to 28 months

  6. Clinical Benefit Rate

    Clinical benefit rate was assessed according to RECIST 1.0 and defined as the percentage of participants who experienced a CR, PR, or stable disease (SD) for at least 6 months. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.

    Time frame: up to 28 months

  7. Time to Progression

    Time to progression was defined as the time from the date of enrollment until the date of progressive disease.

    Time frame: From the date of enrollment until the date of progressive disease (up to 28 months)

07

Results

Posted Dec 29, 2016

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab
Started32
Completed28
Not completed4
Withdrew: Withdrawal by subject2
Withdrew: Participant did not return for treatment1
Withdrew: Violated selection criteria1

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 and was defined as the time from the date when the participant signed the informed consent form (ICF) until death or progressive disease (PD). PD was defined as 20% increase in the sum of the longest diameter of target lesions. PFS and associated confidence intervals were calculated using the Kaplan-Meier method.

Time frame:
From the date of informed consent to the date of death or progressive disease (up to 28 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsTrastuzumab
Progression-Free Survival (PFS)9.9 (6.28 to 13.63)
SecondaryOverall Response Rate

Overall response rate was assessed using RECIST 1.0 and defined as the percentage of participants that achieved a complete response (CR) or a partial response (PR). CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions.

Time frame:
up to 28 months
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsTastuzumab
Overall Response Rate81.3 (63.6 to 92.8)
SecondaryDuration of Response

Duration of response was defined as the time from when a PR or CR was first documented until the date of documented PD or death. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. PD was defined as 20% increase in the sum of the longest diameter of target lesions.

Time frame:
From the time of PR or CR until the date of PD or death (up to 28 months)
Reported as:
Median · months
Duration of Response
monthsTrastuzumab
Duration of Response9.8 (5.82 to 11.60)
SecondaryOverall Survival

Overall survival was defined as the time from the date of enrollment to the date of death due to any cause.

Time frame:
Time from enrollment to the date of death (up to 28 months)
Reported as:
Median · months
Overall Survival
monthsTrastuzumab
Overall SurvivalNA (22.64 to NA)
SecondaryPercentage of Participants With an Adverse Event (AE)

An AE was defined as any adverse medical event that occurred after the participant used the investigational medicinal product (IMP) or other intervention behaviors specified by the protocol in the clinical trial regardless of relationship to the study treatment.

Time frame:
Up to 28 days after last infusion of the study drug (28 months)
Reported as:
Number · percentage of participants
Percentage of Participants With an Adverse Event (AE)
percentage of participantsTrastuzumab
Percentage of Participants With an Adverse Event (AE)93.8
SecondaryDetermination of Biomarkers Indicative for Response (Serum and Tumour Tissue Analyses)
Time frame:
up to 28 months

No measurements were reported for this outcome.

SecondaryClinical Benefit Rate

Clinical benefit rate was assessed according to RECIST 1.0 and defined as the percentage of participants who experienced a CR, PR, or stable disease (SD) for at least 6 months. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.

Time frame:
up to 28 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate
percentage of participantsTrastuzumab
Clinical Benefit Rate81.3 (63.6 to 92.8)
SecondaryTime to Progression

Time to progression was defined as the time from the date of enrollment until the date of progressive disease.

Time frame:
From the date of enrollment until the date of progressive disease (up to 28 months)
Reported as:
Median · months
Time to Progression
monthsTrastuzumab
Time to Progression9.9 (6.28 to 13.63)

Adverse events

Collected over Up to 28 days after the last dose of the study drug (up to 28 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab—5/32 (15.6%)29/32 (90.6%)
Most frequent serious events
Most frequent serious events
EventTrastuzumab
InfectionInfections and infestations1/32
Upper respiratory tract infectionInfections and infestations1/32
Completed suicidePsychiatric disorders1/32
LeukopeniaBlood and lymphatic system disorders1/32
NeutropeniaBlood and lymphatic system disorders1/32
CataractEye disorders1/32
Most frequent other events
Showing 10 of 33
Most frequent other events
EventTrastuzumab
LeukopeniaBlood and lymphatic system disorders19/32
NeutropeniaBlood and lymphatic system disorders18/32
HypoaesthesiaNervous system disorders11/32
AgranulocytosisBlood and lymphatic system disorders10/32
AlopeciaSkin and subcutaneous tissue disorders7/32
AstheniaGeneral disorders7/32
PyrexiaGeneral disorders6/32
Nail disorderSkin and subcutaneous tissue disorders5/32
Oedema peripheralGeneral disorders5/32
DiarrhoeaGastrointestinal disorders5/32

Baseline characteristics

Intention to treat (ITT) data set is defined as all the participants who are eligible through screening, register and enter the study.

Age, Continuous
Age, Continuous(years)Trastuzumab
Mean48.5 ± 11.61
Gender
Gender(Participants)Trastuzumab
Female32
Male0
08

Study locations

17 sites
  • Beijing, 100021, China
  • Beijing, 100071, China
  • Beijing, 100142, China
  • Beijing, 100730, China
  • Chengdu, 610041, China
  • Guangzhou, 510060, China
  • Guangzhou, 510515, China
  • Guangzhou, China
  • Hangzhou, 310009, China
  • Hangzhou, 310022, China
  • Harbin, 150081, China
  • Nanjing, 210009, China
  • Shanghai, 200032, China
  • Shenyang, 110001, China
  • Wuhan, 430022, China
  • Wuhan, 430030, China
  • Zhengzhou, 450008, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2011
First posted
Feb 23, 2011
Start
Mar 2011
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Dec 29, 2016
Last update
Dec 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01301729
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 23, 2011
Start date
Mar 2011
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Dec 29, 2016
Last update
Dec 29, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion